{
    "name": "measles mumps and rubella vaccine, live",
    "comment": "Rx",
    "other_names": [
        "M-M-R II",
        "Priorix"
    ],
    "classes": [
        "Vaccines",
        "Live",
        "Viral"
    ],
    "source": "https://reference.medscape.com/drug/mmrii-priorix-measles-mumps-and-rubella-vaccine-live-343159",
    "pregnancy": {
        "common": [
            "Contraindicated during pregnancy; avoid pregnancy for 3 months following vaccination",
            "In a 10-year survey involving over 700 pregnant women who received rubella vaccine within 3 months before or after conception (of whom 189 received the Wistar RA 27/3 strain), none of the newborns had abnormalities compatible with congenital rubella syndrome",
            "Mumps infection during the first trimester of pregnancy may increase the rate of spontaneous abortion",
            "Although mumps vaccine virus has been shown to infect the placenta and fetus, there is no evidence that it causes congenital malformations in humans",
            "Reports have indicated that contracting wild-type measles during pregnancy enhances fetal risk; increased rates of spontaneous abortion, stillbirth, congenital defects and prematurity have been observed subsequent to infection with wild-type measles during pregnancy",
            "There are no adequate studies of the attenuated (vaccine) strain of measles virus in pregnancy; however, it would be prudent to assume that the vaccine strain of virus is also capable of inducing adverse fetal effects"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown if measles or mumps vaccine is secreted in human milk",
            "The prescribing information describes studies that have shown lactating postpartum women immunized with live attenuated rubella vaccine may secrete the virus in breast milk and transmit it to breastfed infants"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Pregnancy (see Pregnancy and Lactation)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Caution when administering MMRV to persons with a history of cerebral injury, individual or family history of convulsions, or any other condition in which stress due to fever should be avoided",
                "History of anaphylactic or other immediate hypersensitivity reactions (eg, hives, laryngeal edema, difficulty breathing, hypotension, or shock) subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions after receiving vaccines containing traces of chick embryo antigen; carefully evaluate the potential risk-to-benefit ratio before considering vaccination",
                "Neomycin allergy most often manifests as contact dermatitis, which is not a contraindication to receiving the vaccine",
                "Transient thrombocytopenia reported within 4-6 weeks following vaccination with measles, mumps and rubella vaccine; carefully evaluate potential risk and benefit of vaccination in children with thrombocytopenia or in those who experienced thrombocytopenia after vaccination with a previous dose of measles, mumps, and rubella vaccine",
                "Safety and efficacy for postexposure prophylaxis have not been established",
                "Safety and efficacy in HIV-infected children have not been established",
                "Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individualâ€™s immune status has been evaluated and the individual has been found to be immunocompetent",
                "Postmarketing reports suggest transmission of vaccine virus may occur to high-risk individuals (eg, immunocompromised, pregnant women without positive varicella history or vaccination, or newborn infants of mothers without positive varicella history)",
                "Contains albumin; theoretical risk for transmission Creutzfeldt-Jacob disease"
            ],
            "specific": [
                {
                    "type": "Febrile seizures",
                    "description": [
                        "There is a risk of fever and associated febrile seizure in first 2 weeks following immunization with M-M-RII vaccine; for children who have experienced a previous febrile seizure (from any cause) and those with a family history of febrile seizures there is a small increase in risk of febrile seizure following receipt of M-M-RII vaccine",
                        "Administration of MMRV (dose 1) to children aged 12-23 months who have not been previously vaccinated against measles, mumps, rubella, or varicella, nor had a history of the wild-type infections, is associated with higher rates of fever and febrile seizures at 5-12 days after vaccination when compared with children vaccinated with dose 1 of both MMR and varicella vaccine administered separately"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Immune globulins and transfusion",
                        "Immune globulins (IG) and other blood products coadministered with MMRV contain antibodies that may interfere with vaccine virus replication and decrease the expected immune response",
                        "Defer vaccination; appropriate suggested interval between transfusion or IG administration and vaccination will vary with the type of transfusion or indication for, and dose of, IG (eg, 5 months for varicella zoster immune globulin)",
                        "Refer to prescribing information for specific recommendations",
                        "Salicylates",
                        "Reye syndrome reported following salicylate administration during wild-type varicella infection",
                        "Avoid salicylates for 6 weeks after vaccination",
                        "Corticosteroids and immunosuppressive drugs",
                        "Do not administer to individuals receiving immunosuppressive doses of corticosteroids or other immunosuppressive drugs",
                        "Can result in a more extensive vaccine-associated rash or disseminated disease in individuals on immunosuppressive drugs (see Contraindications)",
                        "Use with other vaccines",
                        "At least 1 month should elapse between a dose of a measles-containing vaccine (eg, MMR) and a dose of MMRV, and at least 3 months should elapse between administration of 2 doses of MMRV or varicella-containing vaccines",
                        "Lab tests",
                        "MMR vaccine given individually may result in a temporary depression of tuberculin skin sensitivity",
                        "Therefore, if a tuberculin test is to be done, it should be administered either any time before, simultaneously with, or at least 4 to 6 weeks after MMRV"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "belimumab",
            "description": {
                "common": "belimumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "certolizumab pegol decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "ibrutinib decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo. after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ixekizumab",
            "description": {
                "common": "ixekizumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "mechlorethamine decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "melphalan",
            "description": {
                "common": "melphalan decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo. after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "methotrexate",
            "description": {
                "common": "methotrexate decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunization with live virus vaccines is generally not recommended."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "onasemnogene abeparvovec",
            "description": {
                "common": "onasemnogene abeparvovec decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Adjust vaccinations to accommodate concomitant corticosteroid administration prior to and following onasemnogene abeparvovec infusion. Avoid live vaccines for at least 1 month when initiating or after high-dose systemic corticosteroid therapy administered for =2 weeks."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo. after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "secukinumab",
            "description": {
                "common": "secukinumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Secukinumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating secukinumab, complete all age appropriate immunizations."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ustekinumab",
            "description": {
                "common": "ustekinumab decreases effects of measles mumps and rubella vaccine, live by Mechanism: pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abrocitinib",
            "description": {
                "common": "abrocitinib decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administration of live vaccines is not recommended during abrocitinib treatment and immediately before or after treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adalimumab",
            "description": {
                "common": "adalimumab decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alefacept",
            "description": {
                "common": "alefacept decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anakinra",
            "description": {
                "common": "anakinra decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anifrolumab",
            "description": {
                "common": "anifrolumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Before initiation, update immunization according to current guidelines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithymocyte globulin equine",
            "description": {
                "common": "antithymocyte globulin equine decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithymocyte globulin rabbit",
            "description": {
                "common": "antithymocyte globulin rabbit decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atoltivimab/maftivimab/odesivimab",
            "description": {
                "common": "atoltivimab/maftivimab/odesivimab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Ebola monoclonal antibodies may interfere with immune response of live vaccines. Refer to vaccine guidelines for vaccination timing during and following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "axicabtagene ciloleucel decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid live virus vaccines for at least 6 weeks before initiating lymphodepleting therapy, during axicabtagene ciloleucel treatment, and after treatment until full immune recovery is achieved."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "azathioprine",
            "description": {
                "common": "azathioprine decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "baricitinib",
            "description": {
                "common": "baricitinib decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "basiliximab",
            "description": {
                "common": "basiliximab decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "brexucabtagene autoleucel decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid live virus vaccines for at least 6 weeks before initiating lymphodepleting therapy, during brexucabtagene autoleucel treatment, and after treatment until full immune recovery is achieved."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "budesonide",
            "description": {
                "common": "budesonide decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabazitaxel",
            "description": {
                "common": "cabazitaxel decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Live attenuated vaccines should not be used in patients receiving immunosuppressive therapy. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "canakinumab",
            "description": {
                "common": "canakinumab decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "ciltacabtagene autoleucel decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Avoid live vaccines in immunocompromised patients due to the risk of developing a clinical infection from the live vaccine. Inadequate immune response to the vaccine may also occur in the presence of immunosuppressants. Avoid live vaccines for at least 3 months after cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deflazacort",
            "description": {
                "common": "deflazacort decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dupilumab",
            "description": {
                "common": "dupilumab, measles mumps and rubella vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating dupilumab, complete all age appropriate immunizations. Avoid use of live vaccines in patients treated with dupilumab."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elivaldogene autotemcel",
            "description": {
                "common": "elivaldogene autotemcel, measles mumps and rubella vaccine, live.\nEither decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etanercept",
            "description": {
                "common": "etanercept decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "everolimus",
            "description": {
                "common": "everolimus decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fingolimod",
            "description": {
                "common": "fingolimod decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid live attenuated vaccines during and for 2 months after stopping fingolimod."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glatiramer",
            "description": {
                "common": "glatiramer decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "golimumab",
            "description": {
                "common": "golimumab decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "guselkumab",
            "description": {
                "common": "guselkumab, measles mumps and rubella vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating guselkumab, complete all age appropriate immunizations. No data available on the ability of live or inactive vaccine to elicit an immune response in patients treated with guselkumab."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxychloroquine sulfate",
            "description": {
                "common": "hydroxychloroquine sulfate decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "hydroxyurea decreases effects of measles mumps and rubella vaccine, live by Other (see comment). Avoid or Use Alternate Drug. \nComment: Vaccination with live vaccines in a patient receiving hydroxyurea may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "idecabtagene vicleucel decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "infliximab",
            "description": {
                "common": "infliximab decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leflunomide",
            "description": {
                "common": "leflunomide decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mercaptopurine",
            "description": {
                "common": "mercaptopurine decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "muromonab CD3",
            "description": {
                "common": "muromonab CD3 decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "mycophenolate decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ocrelizumab",
            "description": {
                "common": "ocrelizumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live-attenuated or live vaccines is not recommended during ocrelizumab treatment and until B-cell repletion."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of ofatumumab SC for live or live-attenuated vaccines, and whenever possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live-attenuated vaccines with ozanimod during treatment and for up to 3 months after discontinuing ozanimod. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live attenuated vaccines at least 1 month before initiating, during, and for 1-2 weeks after treatment. Coadministration with live attenuated vaccines may increase infection risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rilonacept",
            "description": {
                "common": "rilonacept decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "risankizumab",
            "description": {
                "common": "risankizumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting risankizumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rituximab",
            "description": {
                "common": "rituximab, measles mumps and rubella vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rituximab-hyaluronidase",
            "description": {
                "common": "rituximab-hyaluronidase, measles mumps and rubella vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "satralizumab",
            "description": {
                "common": "satralizumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. ive vaccines are not recommended during treatment. Administer all immunizations according to immunization guidelines. At least 4 weeks before initiating for live or live-attenuated vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Pause vaccinations beginning 1 week before initiating siponimod and for 4 weeks after stopping treatment. Coadministration with live attenuated vaccines may increase infection risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirolimus",
            "description": {
                "common": "sirolimus decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "temsirolimus",
            "description": {
                "common": "temsirolimus decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "teplizumab",
            "description": {
                "common": "teplizumab decreases effects of measles mumps and rubella vaccine, live by Other (see comment). Avoid or Use Alternate Drug. \nComment: Administer all age-appropriate vaccinations before starting teplizumab. Live-attenuated vaccines are not recommended within 8 weeks before teplizumab treatment, during treatment, or up to 52 weeks after treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tildrakizumab",
            "description": {
                "common": "tildrakizumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Before initiating tildrakizumab therapy, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with tildrakizumab. No data are available on the response to live or inactive vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "tisagenlecleucel decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tocilizumab",
            "description": {
                "common": "tocilizumab decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tralokinumab",
            "description": {
                "common": "tralokinumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "upadacitinib",
            "description": {
                "common": "upadacitinib decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ustekinumab",
            "description": {
                "common": "ustekinumab decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vedolizumab",
            "description": {
                "common": "vedolizumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live virus vaccines while receiving vedolizumab; live vaccines may be administered concurrently with vedolizumab only if the benefits outweigh the risks."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anthrax immune globulin",
            "description": {
                "common": "anthrax immune globulin decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belatacept",
            "description": {
                "common": "belatacept decreases effects of measles mumps and rubella vaccine, live by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betibeglogene autotemcel",
            "description": {
                "common": "betibeglogene autotemcel, measles mumps and rubella vaccine, live. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cytomegalovirus immune globulin (CMV IG)",
            "description": {
                "common": "cytomegalovirus immune globulin (CMV IG) decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "dengue vaccine, measles mumps and rubella vaccine, live. unspecified interaction mechanism. Use Caution/Monitor. Data are not available to establish safety and immunogenicity of coadministration of dengue vaccine with recommended adolescent vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis B immune globulin (HBIG)",
            "description": {
                "common": "hepatitis B immune globulin (HBIG) decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "immune globulin IM (IGIM)",
            "description": {
                "common": "immune globulin IM (IGIM) decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "immune globulin IV (IGIV)",
            "description": {
                "common": "immune globulin IV (IGIV) decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "immune globulin SC",
            "description": {
                "common": "immune globulin SC decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Use Caution/Monitor. Live, attenuated vaccinations may be less effective if administered during leniolisib treatment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "obinutuzumab",
            "description": {
                "common": "obinutuzumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabies immune globulin, human (RIG)",
            "description": {
                "common": "rabies immune globulin, human (RIG) decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetanus immune globulin (TIG)",
            "description": {
                "common": "tetanus immune globulin (TIG) decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines at least 4 weeks before initiating ublituximab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks before initiating for non-live vaccines. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to ublituximab during pregnancy, before confirming recovery of B-cell counts as measured by CD19+ B cells."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vaccinia immune globulin intravenous",
            "description": {
                "common": "vaccinia immune globulin intravenous decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Defer live vaccines for 3 months after immune globulin administration."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chloroquine",
            "description": {
                "common": "chloroquine decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "Rho(D) immune globulin",
            "description": {
                "common": "Rho(D) immune globulin decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Minor/Significance Unknown. Separate by 3 months."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System",
            "percent": "1-800"
        },
        {
            "name": "VAERS",
            "percent": "822-7967"
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Ataxia",
            "percent": null
        },
        {
            "name": "Pain at site",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Lymphadenopathy",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Optic neuritis",
            "percent": null
        },
        {
            "name": "Encephalitis",
            "percent": null
        },
        {
            "name": "Malaise",
            "percent": null
        },
        {
            "name": "Irritability",
            "percent": null
        },
        {
            "name": "Guillain",
            "percent": null
        },
        {
            "name": "Barre synd",
            "percent": null
        },
        {
            "name": "Subacute sclerosing panencephalitis",
            "percent": null
        },
        {
            "name": "rare",
            "percent": null
        },
        {
            "name": "Seizures",
            "percent": null
        },
        {
            "name": "Parotitis",
            "percent": null
        },
        {
            "name": "Bronchospasm",
            "percent": null
        },
        {
            "name": "Leukocytosis",
            "percent": null
        },
        {
            "name": "Conjunctivitis",
            "percent": null
        },
        {
            "name": "Otitis media",
            "percent": null
        },
        {
            "name": "Nerve deafness",
            "percent": null
        }
    ]
}